기금 모금 및 인수 합병 실사를 위한 모범 사례 - 최악의 상황을 피하고 기업가치를 최대화하는 방법
인수 합병 거래 중 예상하지 못한 일이 벌어진다면 거래의 지연을 야기할 수 있으며 심지어 거래를 완전히 무마시킬 수도 있습니다. 그러나 그러한 상황을 대비하여 불미스러운 일을 피할 수 있습니다.
이 백서에서는 다음과 같은 주제에 대해 배우실 수 있습니다:
- 실사 과정에서 피해야 할 실수
- 성공적인 인수 합병 거래의 모범 사례
-
실사 절차의 속도를 높이는 방법
OUR CONTRIBUTORS:

Richard Andersen
Founder, Chief Executive Officer, ShareVault
Richard Andersen
is an experienced Silicon Valley software entrepreneur who has spent
the past 20 years bringing innovative business software, e-commerce, and
financial services solutions to market. His areas of expertise include
product management, sales & marketing, business development, team
building, global expansion, information technology, and operational
efficiency.
Richard began his career at Apple where he developed a lifelong passion for innovation excellence. Early recognition for intrapreneurship at Apple encouraged him to pursue technology management roles at companies including Portfolio Software, Ernst & Young Consulting (clients included Netscape, Novellus, Nextel, and Infoseek), MarketFirst Software, and eBay.
He founded and leads ShareVault where an energized team of professionals are steadfastly blending elements from the enterprise collaboration, productivity, and security spaces into an entirely new enterprise platform for connecting and sharing. He has earned a BA from Whitworth University and an MBA from the University of California, Berkeley.

John Pennett, CPA
Partner-in-Charge of the Life Sciences Group and Technology Group, EisnerAmper
John
Pennett has 30 years of public accounting experience, with a strong
emphasis on public and private life science and technology companies.
John is a frequent writer and speaker on topics related to issues
impacting businesses in the life sciences and technology space. He is
the publisher of Catalyst, a magazine focused
solely on issues related to life sciences and pharmaceutical companies.
John supports entrepreneurial organizations around the country with
content and program development, and serves as a mentor to several early-stage companies.
John has led the accounting, auditing and
strategic advisory work for more than a hundred IPOs, private financing
and mergers and acquisitions with an aggregate valuation in excess of
$1 billion. In addition, he has served as the interim lead
of the firm’s Risk Advisory Practice, leading internal audit, contract
compliance and Sarbanes-Oxley implementation and testing. John
previously worked as an Audit Partner for an international accounting
and consulting firm.

James Burden
President, Dorset Capital, LLC
James E. Burden has over 40 years of experience in corporate finance, law practice, and business operations and is President and majority owner of Dorset Capital, LLC.
Mr. Burden’s involvement with co-founding, financing and operating companies in the U.S. and United Kingdom commenced in the 1980s when he was elected an Underwriting Member/Name of Lloyd’s of London. Through his Lloyd’s connections in the City of London, he began working with Small and Medium Enterprises in the U.K.
Dorset
is assisting Par Equity, a UK-based venture capital firm, expand to the
United States. The first focus area will be investing in digital health
Par Equity USA expanding Par Equity, a UK-based venture capital firm
founded in 2009, to the United States. The second focus area will be the
Par Transatlantic HealthTech Fund I (the “Fund”) investing in digital
health technology companies with proprietary products that are, or are
close to, generating revenue where transatlantic expansion can
accelerate the next stage of their growth. Digital technologies provide
new solutions to address the increasing costs of healthcare and develop
more cost-effective models of personalized patient medical care.
HealthTech includes patient monitoring, wearable medical devices,
robotics, diagnostics and imaging, secure data management and genomic
screening. The Fund will focus on companies suitable for expansion from
the U.K. to the U.S. and companies expanding from the U.S. to the U.K.
Transatlantic expansion is a milestone that can trigger a valuation
inflection and significant returns to the Fund.
In 2001, Mr. Burden was a founding director of EuroGen
Pharmaceuticals Ltd., a U.K. company formed to seek European regulatory
approvals of a NASDAQ-listed company’s drug portfolio. He also was a
founding director of Gloucestershire Innovation Centre, which was formed
to develop and manage incubation facilities in the Bank of England’s
Southgate House in the center of Gloucester, England. Partners included
St. John’s College Cambridge Innovation Centre, the University of
Gloucestershire, and HSBC Bank.
In 2005, he was a founding director of Emiliem, Inc., a Delaware corporation. Emiliem, Inc is a private biotechnology company currently focused on all aspects of the drug discovery and development process. This includes understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions, and diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.
Mr.
Burden received a B.S. degree from the School of Business
Administration, University of California, Berkeley (Haas School of
Business), a J.D. degree from the University of California, Hastings
College of Law, and did post-J.D. studies at the Graduate School of Law,
University of Southern California. He is an active member of the
California State Bar, a member of The Faculty Club, University of
California, Berkeley, and a Fellow of the Institute of Directors,
London.
OUR SPONSORS:

